3.026EUR-1.63%Mkt Cap: 304.45M EURP/E: —Last update: 2026-06-01
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and g…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap304.45M EUR
Enterprise Value306.58M EUR
Revenue (TTM)75.11M EUR
Gross Profit63.15M EUR
Net Income (TTM)-67.59M EUR
Revenue/Share0.7480 EUR
Last Price3.026 EUR
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees224
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0010425595
Valuation
P/E (Trailing)—
P/E (Forward)-1.95
PEG—
EV/EBITDA-9.25
EV/Revenue4.08
P/S4.12
P/B6.00
EPS (TTM)-0.58
EPS (Forward)-1.58
52W Range
1.23450% of range4.840
52W High4.840 EUR
52W Low1.234 EUR
Profitability
Gross Margin86.57%
Oper. Margin-333.43%
EBITDA Margin-44.11%
Profit Margin-92.66%
ROE-89.05%
ROA-20.82%
Growth
Revenue Growth-37.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-39.40M EUR
CapEx (TTM)3.53M EUR
FCF Margin-71.30%
FCF Yield-17.59%
Net Debt-2.64M EUR
Net Debt/EBITDA0.08
Balance Sheet
Debt/Equity1.20
Current Ratio1.52
Quick Ratio0.35
Book Value/Sh0.5130 EUR
Cash/Share0.3470 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)6.500 EUR
Target Range6.500 EUR – 6.500 EUR
# Analysts1
Ownership
Shares Out.72.61M
Float64.64M
Insiders48.01%
Institutions8.74%
Technical
SMA 503.232 (-6.4%)
SMA 2003.327 (-9.1%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)236.83K
Avg Vol (10d)278.31K
Technical Indicators
RSI (14)42.9
MACD-0.0499
MACD Signal-0.0228
MACD Hist.-0.0271
BB Upper3.596 EUR
BB Middle3.269 EUR
BB Lower2.943 EUR
BB Width19.97%
ATR (14)0.2172 EUR
Vol Ratio (20d)1.15x